| WB | 1/500 - 1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | HGF; HSF; BSF2; IL-6; IFNB2 |
| Entrez GeneID | 3569 |
| clone | 6D9A1 |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat,Monkey |
| Immunogen | Purified recombinant fragment of human IL-6 expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于IL-6抗体的3-4篇参考文献及其摘要的简要概括：
---
1. **文献名称**：*Interleukin-6 Receptor Inhibition with Tocilizumab Reduces Mortality in COVID-19 Patients with Hyperinflammatory Phenotype*
**作者**：Hermine, O. et al.
**摘要**：该研究报道了IL-6受体抗体托珠单抗(Tocilizumab)在COVID-19重症患者中的随机对照试验结果。结果显示，与标准治疗相比，托珠单抗显著降低了炎症标志物水平，并减少了机械通气需求和28天死亡率，尤其在伴有细胞因子风暴的患者中效果更显著。
2. **文献名称**：*Targeting IL-6 in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Tocilizumab Therapy*
**作者**：Sackesen, C. et al.
**摘要**：这篇系统综述分析了托珠单抗治疗类风湿性关节炎(RA)的多项临床试验数据，表明其通过阻断IL-6信号通路显著缓解关节症状、抑制骨侵蚀，并改善患者生活质量，长期使用安全性良好。
3. **文献名称**：*Siltuximab in Multicentric Castleman’s Disease: A Phase III Randomized Trial*
**作者**：Kurzrock, R. et al.
**摘要**：研究评估了IL-6抗体司妥昔单抗(Siltuximab)治疗多中心型Castleman病(MCD)的效果。III期试验表明，与安慰剂相比，司妥昔单抗显著提高肿瘤缓解率和无进展生存期，且耐受性良好，成为MCD的一线治疗方案。
4. **文献名称**：*IL-6 in Inflammation, Autoimmunity, and Cancer: Comprehensive Insights into Molecular Mechanisms*
**作者**：Rose-John, S.
**摘要**：这篇综述详细解析了IL-6在慢性炎症、自身免疫病及癌症中的双重作用，强调其通过经典和反式信号通路驱动疾病进展，并总结了靶向IL-6/IL-6R抗体的临床潜力及未来研究方向。
---
以上文献涵盖了IL-6抗体在炎症性疾病、病毒感染并发症及肿瘤治疗中的应用，以及基础机制研究，可支持相关领域的学术探讨。
Interleukin-6 (IL-6) is a pleiotropic cytokine involved in immune regulation, inflammation, hematopoiesis, and metabolism. Dysregulated IL-6 signaling is implicated in autoimmune diseases (e.g., rheumatoid arthritis), chronic inflammation, and cancers. IL-6 binds to its receptor (IL-6R), activating JAK/STAT pathways and promoting pro-inflammatory responses. Targeting IL-6 or its signaling has emerged as a therapeutic strategy.
IL-6 antibodies include **tocilizumab** (anti-IL-6R) and **siltuximab** (anti-IL-6), approved for conditions like rheumatoid arthritis and Castleman’s disease. These monoclonal antibodies block IL-6-mediated signaling, reducing inflammation and disease progression. During the COVID-19 pandemic, tocilizumab gained attention for mitigating cytokine storms in severe cases.
Research continues to explore IL-6 antibodies in oncology, as IL-6 promotes tumor growth and metastasis. Challenges include managing side effects (e.g., infections, liver toxicity) and optimizing efficacy through combination therapies. Emerging next-gen agents, like satralizumab (anti-IL-6R for neuromyelitis optica), highlight expanding clinical applications.
Overall, IL-6 antibodies represent a cornerstone in biologics, offering targeted modulation of inflammatory pathways with transformative outcomes in diverse diseases. Ongoing studies aim to refine their use and uncover novel indications.
×
